Col on Nostr: The Danish drugmaker Novo Nordisk argues that the “unusually high” prices it ...

The Danish drugmaker Novo Nordisk argues that the “unusually high” prices it charges for weight-loss drugs Ozempic and Wegovy are justified because of all the money it poured into developing them, says Bloomberg. Which is fair enough, except for the fact that by the end of this year the company will have already made $65bn from those two drugs – more than its “entire research budget for the past three decades”.